Cancer biologist Cyrus Ghajar was gearing as much as examine how the immune system can battle breast most cancers when he hit a snag: The supposedly fast-spreading most cancers cells he implanted in mice stayed put and typically even disappeared after about 11 days. Then postdoc Candice Grzelak recognized the wrongdoer: the inexperienced fluorescent protein (GFP) the researchers had been utilizing to trace the cells. The marker itself was stimulating the rodents’ immune system to assault the tumor cells.
Ghajar’s lab on the Fred Hutchinson Cancer Research Center bought round this sudden downside, which it described in a paper final month. But he and others say the lab’s expertise displays a broader situation in mouse research of immunotherapies, highly effective remedies that harness the immune system to conquer tumors: The glowing proteins biologists use to trace the most cancers cells, usually borrowed from fireflies or jellyfish, could also be scary their very own immune assault on the cells.
Other international proteins which can be workhorses of lab research, similar to elements of the genome editor CRISPR, may have the identical impact. And the phenomenon may clarify why labs typically can’t reproduce immunotherapy findings from different teams, suggests Glenn Merlino, a most cancers biologist on the National Cancer Institute (NCI).
As immunotherapy turns into increasingly essential, he provides, scientists want to pay attention to confounding elements like this. “So many preclinical experiments do not end up telling you anything useful in the clinic,” says Merlino, a co-author on commentary on the difficulty at the moment in Cancer Cell.
Although it’s lengthy been recognized that the immune system can sense marker proteins similar to GFP as international, it didn’t a lot matter for most cancers research. That’s as a result of most labs used mice missing an immune system so they’d not reject the transplanted human most cancers cells usually used to evaluate remedies.
But as immunotherapies have taken off in previous decade, extra labs are working with mice which have intact immune techniques. Ghajar and others shifted to mouse most cancers cells, which aren’t instantly rejected. Others use mice which have humanized immune techniques and settle for human most cancers cells.
Ghajar’s lab realized its mice had been producing immune sentinels known as T cells that attacked the GFP-labeled cells, blocking their progress. They lowered the degrees of GFP, however the most cancers cells nonetheless didn’t metastasize. In the top, the group discovered the most effective resolution was to trick the mouse immune system into considering the GFP was a pure protein, through the use of mice engineered to supply GFP in sure immune cells often known as dendritic cells, which induce tolerance. In these rodents, the breast most cancers cells grew as anticipated, they reported in Cancer Cell.
“We wanted to draw attention to the problem and provide the field with reagents and metrics necessary to solve it,” Ghajar says.
Merlino and his NCI co-authors warn of their commentary that the identical problematic immune response may come up in experiments utilizing different glowing proteins from numerous species, viral proteins that trigger most cancers, and even Cas9, CRISPR’s DNA-cutting enzyme, which comes from a bacterium. Researchers may have to seek out workarounds, similar to mouse strains modified in order that they tolerate the international proteins, just like the mice turned to by Ghajar’s lab. Merlino requires different researchers to share related experiences, maybe in a database.
Peter Friedl, who research metastasis at Radboud University and the MD Anderson Cancer Center, says he, too, has had experiments fail due to an immune response to a nonmouse marker protein. Researchers have fingered different causes for most cancers biology’s replication downside, similar to variations in mouse colony microbiomes. But the sudden immune responses, Friedl says, “absolutely” may contribute.
